LeonaBio, Inc.

LONA

LeonaBio, Inc.

LONA

Insider Sentiment (TTM):

Last Purchase:2024-06-24Last Sale:2026-03-04Shares Purchased (TTM):0Shares Sold (TTM):16,748

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:6,443,734Shares Outstanding:19,027,087Institutional Ownership Pct.:33.87%

Earnings Market Reaction:

Filing Date:2026-08-14Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	32	33	69	21	20	26	48	69	74	78	91	110
Restricted Cash Current	-	-	-	-	-	-	-	8	8	-	-	-
Short Term Investments	19	35	19	4	10	10	3	-	18	44	57	63
Prepaid Expense And Other Assets Current	4	2	1	2	2	3	4	3	5	5	6	6
Insurance Settlements Receivable Current	-	-	-	-	-	-	-	2	2	2	2	-
Assets Current	55	69	89	27	32	40	55	82	107	129	155	179
Restricted Cash Noncurrent	1	1	1	1	1	1	1	1	1	1	1	1
Property Plant And Equipment Net	1	1	1	2	2	2	2	3	3	3	3	4
Operating Lease Right Of Use Asset	0	0	1	1	1	1	1	1	1	1	1	1
Other Assets Noncurrent	0	0	0	0	0	0	0	0	0	0	0	1
Assets	57	72	92	30	36	44	59	86	111	133	160	185
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	2	2	5	0	0	1	0	0	0	1	0	2
Accrued Liabilities Current	5	4	5	2	2	4	12	17	16	15	18	17
Loss Contingency Accrual Carrying Value Current	-	-	-	-	-	-	-	10	10	10	10	10
Operating Lease Liability Current	0	0	0	0	0	0	0	0	0	0	0	0
Liabilities Current	8	7	48	3	3	5	13	28	27	26	29	29
Operating Lease Liability Noncurrent	0	0	0	0	1	1	1	1	1	1	1	1
Other Liabilities Noncurrent	1	1	1	-	-	-	-	-	-	-	-	-
Liabilities	23	22	64	3	4	6	14	29	28	27	30	30
Stockholders Equity
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	597	594	540	456	454	453	451	449	446	442	440	437
Accumulated Other Comprehensive Income Loss Net Of…	-0	-0	-0	-0	-0	-0	0	0	-0	-0	-0	-1
Retained Earnings Accumulated Deficit	-564	-545	-512	-429	-422	-415	-406	-391	-362	-336	-309	-282
Stockholders Equity	34	49	28	27	32	37	45	58	83	107	130	155
Liabilities And Stockholders Equity	57	72	92	30	36	44	59	86	111	133	160	185
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	400	400	90	900	900	900	90	900	900	900	900	900
Common Stock Shares Issued	9	9	9	4	4	4	4	4	4	4	4	4
Shares Outstanding	9	9	9	4	4	4	4	4	4	4	4	4
Stockholders Equity Note Stock Split Conversion Ra…	-	-	0	0	-	-	-	-	-	-	-	-

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-3.25%	-4.67%	-25.05%	-	-	-	-	-	-	-	-	-
2025	23.23%	16.14%	80.31%	5.14%	4.32%	10.00%	8.48%	86.53%	44.89%	-18.97%	0.49%	-20.43%
2024	15.38%	15.38%	45.25%	2.15%	-86.76%	-85.46%	-12.67%	-26.67%	-26.00%	-21.51%	-43.50%	-35.70%
2023	-	-	-	-	-	-	8.63%	74.82%	122.30%	-33.33%	-37.91%	-46.06%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	7.01	10.38	1.88	9.70	10.81	7.26	4.18	2.95	3.97	5.03	5.37	6.24
Quick Ratio	6.53	10.15	1.86	9.05	10.00	6.68	3.90	2.84	3.78	4.83	5.17	6.04
Working Capital	46.99M	62.54M	41.96M	24.24M	29.24M	34.36M	41.71M	54.25M	79.80M	103.04M	125.89M	149.88M
Leverage & Debt
Debt to Equity	0.69	0.45	2.32	0.12	0.11	0.17	0.31	0.50	0.34	0.25	0.23	0.19
Debt Ratio	0.41	0.31	0.70	0.11	0.10	0.14	0.24	0.33	0.25	0.20	0.19	0.16
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Per Share Metrics
Diluted EPS TTM	-5.96	-6.80	-24.70	-9.56	-15.31	-20.43	-25.19	-28.36	-29.56	-30.32	-30.95	-31.67
Free Cash Flow Per Share TTM	-2.35	-2.73	-10.69	-9.55	-14.33	-22.04	-25.26	-25.31	-25.66	-26.21	-26.58	-23.76
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Growth Metrics
Net Income Growth (1Y)	136.34%	62.28%	8.94%	-65.46%	-47.24%	-31.37%	-17.62%	-9.38%	5.30%	13.38%	23.04%	47.26%
EPS Growth (1Y)	-61.06%	-66.70%	-1.96%	-66.27%	-48.21%	-32.63%	-18.60%	-10.47%	4.26%	12.20%	22.11%	46.34%
Valuation Metrics
P/E TTM	-1.54	-1.51	-0.31	-0.43	-0.20	-0.14	-0.23	-0.16	-0.90	-0.90	-0.79	-0.64
P/B TTM	6.49	3.97	1.16	0.61	0.37	0.30	0.50	0.30	1.22	0.98	0.71	0.50
Market Cap	218.04M	195.60M	32.37M	16.33M	11.81M	11.13M	22.59M	17.18M	101.71M	105.00M	92.39M	76.87M
Enterprise Value	185.72M	162.77M	-36.91M	-4.55M	-8.08M	-15.29M	-25.85M	-51.68M	27.88M	27.18M	1.81M	-33.46M
Calculated Values
Free Cash Flow TTM	-55.69M	-51.97M	-45.73M	-37.68M	-56.04M	-86.06M	-97.20M	-97.48M	-98.47M	-100.43M	-101.06M	-90.43M
Net Debt	-32.32M	-32.83M	-69.28M	-20.87M	-19.89M	-26.42M	-48.44M	-68.86M	-73.83M	-77.82M	-90.58M	-110.33M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-03-04Sale

Owner: Renninger, Robert

Title: CHIEF FINANCIAL OFFICER

Shares: 906

Price/Share: $5.37

Value: $4,865.22

Shares Owned: 15,851

Relationship: Officer

Ownership: Direct

2026-03-04Sale

Owner: Worthington, Mark

Title: GENERAL COUNSEL and CCO

Shares: 1,328

Price/Share: $5.37

Value: $7,131.36

Shares Owned: 18,376

Relationship: Officer

Ownership: Direct

2026-03-04Sale

Owner: Litton, Mark James

Title: PRESIDENT and CEO

Shares: 5,156

Price/Share: $5.37

Value: $27,687.72

Shares Owned: 57,926

Relationship: Director,Officer

Ownership: Direct

2026-03-04Sale

Owner: Church, Kevin

Title: CHIEF SCIENTIFIC OFFICER

Shares: 1,359

Price/Share: $5.37

Value: $7,297.83

Shares Owned: 25,178

Relationship: Officer

Ownership: Direct

2026-03-04Sale

Owner: San, Martin Javier

Title: CHIEF MEDICAL OFFICER

Shares: 1,720

Price/Share: $5.37

Value: $9,236.40

Shares Owned: 15,887

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-03-04	Renninger, Robert	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	906	5.37	$4,865.22	15,851	4
2026-03-04	Worthington, Mark	Officer	GENERAL COUNSEL and CCO	Direct	Sale	1,328	5.37	$7,131.36	18,376	4
2026-03-04	Litton, Mark James	Director,Officer	PRESIDENT and CEO	Direct	Sale	5,156	5.37	$27,687.72	57,926	4
2026-03-04	Church, Kevin	Officer	CHIEF SCIENTIFIC OFFICER	Direct	Sale	1,359	5.37	$7,297.83	25,178	4
2026-03-04	San, Martin Javier	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	1,720	5.37	$9,236.40	15,887	4
2026-01-02	Litton, Mark James	Director,Officer	President and CEO	Direct	Sale	2,586	6.88	$17,791.68	40,828	4
2026-01-02	San, Martin Javier	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	1,644	6.88	$11,310.72	10,189	4
2026-01-02	Worthington, Mark	Officer	General Counsel and CCO	Direct	Sale	876	6.88	$6,026.88	13,978	4
2026-01-02	Renninger, Robert	Officer	Chief Financial Officer	Direct	Sale	297	6.88	$2,043.36	12,857	4
2026-01-02	Church, Kevin	Officer	CHIEF SCIENTIFIC OFFICER	Direct	Sale	876	6.88	$6,026.88	20,681	4
2025-07-01	Church, Kevin	Officer	CHIEF SCIENTIFIC OFFICER	Direct	Sale	8,526	0.29	$2,472.54	168,901	4
2025-07-01	Litton, Mark James	Director,Officer	President and CEO	Direct	Sale	25,123	0.29	$7,285.67	325,802	4
2025-07-01	San, Martin Javier	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	10,842	0.29	$3,144.18	71,665	4
2025-07-01	Renninger, Robert	Officer	SVP, Finance and Accounting	Direct	Sale	2,897	0.29	$840.13	109,186	4
2025-07-01	Worthington, Mark	Officer	General Counsel and CCO	Direct	Sale	8,526	0.29	$2,472.54	111,875	4
2025-01-02	Litton, Mark James	Director,Officer	President and CEO	Direct	Sale	25,107	0.56	$14,059.92	242,591	4
2025-01-02	Worthington, Mark	Officer	General Counsel and CCO	Direct	Sale	8,510	0.56	$4,765.60	83,735	4
2025-01-02	Renninger, Robert	Officer	VP of Finance	Direct	Sale	2,881	0.56	$1,613.36	89,724	4
2025-01-02	San, Martin Javier	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	10,826	0.56	$6,062.56	35,841	4
2025-01-02	Church, Kevin	Officer	CHIEF SCIENTIFIC OFFICER	Direct	Sale	8,510	0.56	$4,765.60	130,761	4
2024-09-05	Lenington, Rachel	Officer	COO and CDO	Direct	Sale	2,525	0.57	$1,439.25	20,870	4
2024-09-05	Worthington, Mark	Officer	GENERAL COUNSEL	Direct	Sale	2,525	0.57	$1,439.25	51,927	4
2024-09-05	Gengos, Andrew	Officer	CFO and Chief Business Officer	Direct	Sale	1,272	0.57	$725.04	97,532	4
2024-09-05	Church, Kevin	Officer	CHIEF SCIENTIFIC OFFICER	Direct	Sale	2,525	0.57	$1,439.25	92,684	4
2024-09-05	Litton, Mark James	Director,Officer	President and CEO	Direct	Sale	5,032	0.57	$2,868.24	159,365	4
2024-06-24	Romano, Kelly A	Director	-	Direct	Purchase	27,400	2.42	$66,308.00	80,715	4
2024-01-05	Lenington, Rachel	Officer	Chief Operating Officer	Direct	Sale	2,412	2.91	$7,018.92	13,395	4
2024-01-05	Lenington, Rachel	Officer	COO AND CDO	Direct	Sale	2,412	2.91	$7,018.92	13,395	4/A
2024-01-05	Gengos, Andrew	Officer	CFO AND CHIEF BUSINESS OFFICER	Direct	Sale	1,208	2.91	$3,515.28	83,804	4/A
2024-01-05	Church, Kevin	Officer	CHIEF SCIENTIFIC OFFICER	Direct	Sale	2,412	2.91	$7,018.92	80,256	4/A
2024-01-05	Litton, Mark James	Director,Officer	CEO	Direct	Sale	4,820	2.91	$14,026.20	144,397	4/A
2024-01-05	Worthington, Mark	Officer	GENERAL COUNSEL	Direct	Sale	2,412	2.91	$7,018.92	34,452	4/A
2024-01-05	Litton, Mark James	Director,Officer	Chief Executive Officer	Direct	Sale	4,820	2.91	$14,026.20	144,397	4
2024-01-05	Worthington, Mark	Officer	General Counsel	Direct	Sale	2,412	2.91	$7,018.92	34,452	4
2023-12-29	Edelman, Joseph, Percepti…	Director,TenPercentOwner	-	Indirect	Purchase	163,954	2.38	$390,210.52	5,402,964	4
2023-06-07	Gengos, Andrew	Officer	See Below	Direct	Purchase	15,000	3.40	$51,000.00	80,012	4
2023-06-05	Gengos, Andrew	Officer	See Below	Direct	Purchase	45,000	3.00	$135,000.00	65,012	4
2023-03-30	Pickering, Grant	Director	-	Direct	Purchase	15,000	2.47	$37,050.00	25,783	4
2023-03-29	Johnson, James A	Director	-	Direct	Purchase	5,000	2.40	$12,000.00	5,000	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

33.87%

Inst. Shares: 6,443,734

Shares Outstanding: 19,027,087

2025-12-31

144.25%

Inst. Shares: 6,167,855

Shares Outstanding: 4,275,762

2025-09-30

42.47%

Inst. Shares: 1,675,165

Shares Outstanding: 3,943,887

2025-06-30

Inst. Shares: 17,061,278

Shares Outstanding: 3,909,296

2025-03-31

Inst. Shares: 16,989,694

Shares Outstanding: 3,904,244

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	6,443,734	19,027,087	33.87%
2025-12-31	6,167,855	4,275,762	144.25%
2025-09-30	1,675,165	3,943,887	42.47%
2025-06-30	17,061,278	3,909,296	-
2025-03-31	16,989,694	3,904,244	-
2024-12-31	17,166,008	3,848,044	-
2024-09-30	15,205,562	3,851,758	-
2024-06-30	21,705,829	3,837,973	-
2024-03-31	20,527,885	3,832,157	-
2023-12-31	21,004,499	3,802,018	-
2023-09-30	20,207,806	3,805,458	-
2023-06-30	20,535,622	3,799,958	-
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

LeonaBio, Inc. (LONA) — SEC Financial Statements & Analysis

LeonaBio, Inc. (LONA) is a biological products, (no diagnostic substances) company. LeonaBio, Inc. trades on Nasdaq as: LONA. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), LeonaBio, Inc. reported a Debt-to-Equity ratio of 0.69x, a Price-to-Book (P/B) ratio of 6.49x (TTM), at a market cap of $218.04M. Figures below are sourced from SEC EDGAR, as-filed.

Debt To Equity: 0.69x
P/B TTM: 6.49x
Market Cap: $218.04M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is LeonaBio, Inc. in?

LeonaBio, Inc. (LONA) operates in the Biological Products, (No Diagnostic Substances) industry.

What is LONA's market cap?

LeonaBio, Inc. (LONA) has a market capitalization of $218.04M as of 2026-06-30.

What exchange does LONA trade on?

LeonaBio, Inc. (LONA) trades on the Nasdaq.

LeonaBio, Inc.

Financial Statements

Custom Table

Interactive Financial Visualizations

Earnings Market Reaction

Performance and Valuation Metrics

Insider Transactions

Institutional Ownership

LeonaBio, Inc. (LONA) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Biological Products, (No Diagnostic Substances)

Wall Street's data.
Main Street's price.

LeonaBio, Inc. (LONA) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Biological Products, (No Diagnostic Substances)

Wall Street's data.Main Street's price.

Wall Street's data.
Main Street's price.